Home › Compound Library › Metformin Extended Release (Glucophage XR)

Metformin Extended Release (Glucophage XR)

Antidiabeticprescriptionoral · inferred

Once-daily extended-release metformin. It delays peak concentration to a median of about 7 hours and lowers the peak while providing comparable overall exposure.

Projected serum levels — 500 mg, once daily

Metformin Extended Release (Glucophage XR)
Metformin Extended Release (Glucophage XR) modeled serum levels, 500 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 500 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 94.3 mg, trough ≈ 26.6 mg body load. Population-based estimate over 15 days for a 500 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antidiabetic
Route modeled
Oral
Model confidence
inferred
Half-life
6.2 h
Common dose
500 mg
Suggested maximum
2k mg/day
Reference dose range
500–2k mg (single dose)
Suggested cadence
once daily
Validated against
500 mg oral — Cmax 0.60 mg/L at 7 h

Research behind this entry

  1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study Group · Lancet, 1998 DOI

    Landmark UKPDS trial of 1,704 overweight diabetic patients found metformin reduced diabetes-related death by 42% and all-cause mortality by 36% compared to conventional treatment.

  2. Metformin in the treatment of type 2 diabetes: a review Rena G et al. · Annals of Internal Medicine, 2017 DOI

    Comprehensive review of metformin mechanisms including AMPK activation, mitochondrial complex I inhibition, and emerging evidence for anti-aging and anti-cancer properties.

  3. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls Bannister CA et al. · Diabetes, Obesity and Metabolism, 2014 DOI

    Observational study of 180,000 people found metformin-treated diabetic patients had 15% lower all-cause mortality than matched non-diabetic controls, suggesting longevity benefits.

3 published studies referenced in the app, each with a plain-language summary.